IO Biotech Inc (IOBT)
NASDAQ
News
Market Data
Register to chat with like-minded investors on our interactive forums.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced imm... IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. Show more
Ask ADVFN Intelligence (AI)
-- Enrollment Completed Ahead of Schedule -- -- Initial Data Expected in 2025 -- NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical...
Funds expected to be used to advance IO Biotech’s immune-modulating therapeutic cancer vaccines, including potential BLA submission for IO102-IO103 in 2025Commitment is part of the European...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.9 | 1.055 | 0.8703 | 198630 | 0.95743049 | CS |
| 4 | -0.02 | -2.17391304348 | 0.92 | 1.055 | 0.773 | 152306 | 0.90285757 | CS |
| 12 | -0.39 | -30.2325581395 | 1.29 | 1.29 | 0.66 | 435905 | 0.83857938 | CS |
| 26 | -0.42 | -31.8181818182 | 1.32 | 1.67 | 0.66 | 406900 | 0.96630215 | CS |
| 52 | -0.88 | -49.4382022472 | 1.78 | 1.89 | 0.66 | 272573 | 1.09897956 | CS |
| 156 | -6.96 | -88.5496183206 | 7.86 | 9.77 | 0.66 | 149434 | 1.60036016 | CS |
| 260 | -15.1 | -94.375 | 16 | 17.88 | 0.66 | 149463 | 2.27313603 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
